Brandon Walker Urges Boston Scientific Investors to Reach Out
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: Globenewswire
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if the board breached fiduciary duties to shareholders, particularly following a class action complaint filed on March 5, 2026.
- False Statements Allegations: The lawsuit alleges that Boston Scientific failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the class period from July 23, 2025, to February 3, 2026, misleading investors and impacting the company's market performance.
- Increased Market Competition: Boston Scientific is facing new entrants in the market, which not only diminishes its share in the U.S. electrophysiology sector but also limits the company's growth potential, raising further concerns among investors.
- Shareholder Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them to understand their legal rights and potential claims, ensuring that shareholder interests are adequately protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 61.860
Low
94.00
Averages
108.14
High
132.00
Current: 61.860
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Brandon Walker Urges Boston Scientific Investors to Reach Out
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if the board breached fiduciary duties to shareholders, particularly following a class action complaint filed on March 5, 2026.
- False Statements Allegations: The lawsuit alleges that Boston Scientific failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the class period from July 23, 2025, to February 3, 2026, misleading investors and impacting the company's market performance.
- Increased Market Competition: Boston Scientific is facing new entrants in the market, which not only diminishes its share in the U.S. electrophysiology sector but also limits the company's growth potential, raising further concerns among investors.
- Shareholder Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them to understand their legal rights and potential claims, ensuring that shareholder interests are adequately protected.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific faces a class action for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, leading to misleading investor perceptions about its future prospects, with a lead plaintiff deadline of May 4, 2026, potentially undermining shareholder confidence.
- Eos Energy Lawsuit: Eos Energy is accused in a class action of failing to achieve necessary production ramp-up and experiencing excessive battery line downtime beyond industry norms, with a lead plaintiff deadline of May 5, 2026, which could negatively impact its market share.
- Soleno Therapeutics Lawsuit: Soleno is facing a class action for concealing safety issues in its DCCR clinical trial, with a lead plaintiff deadline of May 5, 2026, which may raise concerns about the commercial viability of its product.
- Nektar Therapeutics Lawsuit: Nektar is being sued for not adhering to applicable standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, which could affect the trial's results and the company's reputation.
See More
Trump Announces U.S.-Iran Ceasefire Agreement
- Market Surge: Following Trump's announcement of a two-week ceasefire between the U.S. and Iran, stocks soared, with S&P 500 futures rising sharply, reflecting market optimism about the potential end of the conflict.
- Crude Price Plunge: The ceasefire led to an 18% drop in West Texas Intermediate futures to around $92 per barrel, while Brent oil fell 16.7%, alleviating inflationary pressures and potentially boosting consumer spending.
- Airline Stocks Rally: Lower crude prices resulted in significant gains for airlines, with United Airlines up over 12% and Delta Air Lines rising about 11%, indicating that reduced fuel costs could enhance profitability and stimulate travel demand.
- Tech Stocks Strengthen: Stocks like Sandisk and On Semiconductor, identified by JPMorgan as inversely correlated with WTI, saw premarket gains of 9% and 5% respectively, suggesting renewed investor confidence in technology amid the positive market sentiment.
See More
CITIGROUP LOWERS TARGET PRICE FOR BOSTON SCIENTIFIC CORP TO $87, DOWN FROM $94
- Target Price Adjustment: Citigroup has reduced its target price for a specific stock from $94 to $87.
- Market Impact: This adjustment reflects Citigroup's updated outlook on the stock's performance in the market.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected individuals to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading investors to misunderstand the growth prospects of its electrophysiology segment, ultimately resulting in a net income miss and investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases.
See More
Boston Scientific Stock Declines Amid Market Trends
- Stock Performance: Boston Scientific (BSX) ended the recent trading session at $61.86, reflecting a -1.17% change from the previous day, underperforming the S&P 500's 0.08% gain, indicating market caution regarding its short-term outlook.
- Monthly Decline: The stock has dropped by 12.95% over the past month, significantly exceeding the Medical sector's 6.98% decline, which may undermine investor confidence in the company's relative strength within the industry.
- Earnings Expectations: The upcoming earnings report, scheduled for April 22, 2026, is projected to reveal an EPS of $0.8, indicating a 6.67% growth year-over-year, with revenue expected at $5.19 billion, up 11.2% from the prior year, potentially providing price support.
- Analyst Ratings: Currently, BSX holds a Zacks Rank of #3 (Hold), with a recent 0.15% decline in EPS estimates; however, its forward P/E ratio of 18.13 is slightly below the industry average of 18.15, suggesting some investment value.
See More
Brandon Walker Urges Boston Scientific Investors to Reach Out
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if the board breached fiduciary duties to shareholders, particularly following a class action complaint filed on March 5, 2026.
- False Statements Allegations: The lawsuit alleges that Boston Scientific failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the class period from July 23, 2025, to February 3, 2026, misleading investors and impacting the company's market performance.
- Increased Market Competition: Boston Scientific is facing new entrants in the market, which not only diminishes its share in the U.S. electrophysiology sector but also limits the company's growth potential, raising further concerns among investors.
- Shareholder Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them to understand their legal rights and potential claims, ensuring that shareholder interests are adequately protected.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific faces a class action for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, leading to misleading investor perceptions about its future prospects, with a lead plaintiff deadline of May 4, 2026, potentially undermining shareholder confidence.
- Eos Energy Lawsuit: Eos Energy is accused in a class action of failing to achieve necessary production ramp-up and experiencing excessive battery line downtime beyond industry norms, with a lead plaintiff deadline of May 5, 2026, which could negatively impact its market share.
- Soleno Therapeutics Lawsuit: Soleno is facing a class action for concealing safety issues in its DCCR clinical trial, with a lead plaintiff deadline of May 5, 2026, which may raise concerns about the commercial viability of its product.
- Nektar Therapeutics Lawsuit: Nektar is being sued for not adhering to applicable standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, which could affect the trial's results and the company's reputation.
See More
Trump Announces U.S.-Iran Ceasefire Agreement
- Market Surge: Following Trump's announcement of a two-week ceasefire between the U.S. and Iran, stocks soared, with S&P 500 futures rising sharply, reflecting market optimism about the potential end of the conflict.
- Crude Price Plunge: The ceasefire led to an 18% drop in West Texas Intermediate futures to around $92 per barrel, while Brent oil fell 16.7%, alleviating inflationary pressures and potentially boosting consumer spending.
- Airline Stocks Rally: Lower crude prices resulted in significant gains for airlines, with United Airlines up over 12% and Delta Air Lines rising about 11%, indicating that reduced fuel costs could enhance profitability and stimulate travel demand.
- Tech Stocks Strengthen: Stocks like Sandisk and On Semiconductor, identified by JPMorgan as inversely correlated with WTI, saw premarket gains of 9% and 5% respectively, suggesting renewed investor confidence in technology amid the positive market sentiment.
See More
CITIGROUP LOWERS TARGET PRICE FOR BOSTON SCIENTIFIC CORP TO $87, DOWN FROM $94
- Target Price Adjustment: Citigroup has reduced its target price for a specific stock from $94 to $87.
- Market Impact: This adjustment reflects Citigroup's updated outlook on the stock's performance in the market.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected individuals to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading investors to misunderstand the growth prospects of its electrophysiology segment, ultimately resulting in a net income miss and investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases.
See More
Boston Scientific Stock Declines Amid Market Trends
- Stock Performance: Boston Scientific (BSX) ended the recent trading session at $61.86, reflecting a -1.17% change from the previous day, underperforming the S&P 500's 0.08% gain, indicating market caution regarding its short-term outlook.
- Monthly Decline: The stock has dropped by 12.95% over the past month, significantly exceeding the Medical sector's 6.98% decline, which may undermine investor confidence in the company's relative strength within the industry.
- Earnings Expectations: The upcoming earnings report, scheduled for April 22, 2026, is projected to reveal an EPS of $0.8, indicating a 6.67% growth year-over-year, with revenue expected at $5.19 billion, up 11.2% from the prior year, potentially providing price support.
- Analyst Ratings: Currently, BSX holds a Zacks Rank of #3 (Hold), with a recent 0.15% decline in EPS estimates; however, its forward P/E ratio of 18.13 is slightly below the industry average of 18.15, suggesting some investment value.
See More
